I'm LongbridgeAI, I can summarize articles.Tevogen Bio Holdings announced its 2026 annual shareholder meeting will be held virtually on August 24, 2026. Key agenda items include electing two Class II directors, ratifying KPMG as the independent auditor for the fiscal year ending December 31, 2026, approving an increase of 100 million shares to the 2024 Omnibus Incentive Plan share reserve, and adopting a charter amendment to permit shareholder action by written consent.
- Tevogen Bio Holdings will hold its 2026 annual meeting in a virtual format on Aug. 24, 2026. * Shareholders will vote on electing two Class II directors to three-year terms. * Items include ratifying KPMG as independent auditor for the fiscal year ending Dec. 31, 2026. * Votes are also set on adding 100,000,000 shares to the 2024 Omnibus Incentive Plan share reserve. * A charter amendment to allow shareholder action by written consent is also up for approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-034442), on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here